gip/glp-1 GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica GIP and GLP-1: similarities and

Clinicians should be aware that the FDA contraindications for products with the thyroid C-cell tumor boxed warning include personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 (MEN 2)

Weight management can be particularly challenging for people with hypothyroidism

New formulations and delivery methods are changing the frequency conversation

In this Review, we summarize current preclinical and clinical evidence, showing that the riskbenefit profile of GLP1RAs remains favourable in individuals with T2DM and obesity, although caution is warranted in those with a low cardiometabolic risk, for whom the potential risks of cancer might outweigh any expected benefits

Improvements were also noted in lipid profiles, blood glucose levels, and insulin resistance, along with substantial enhancements in quality of life and appetite control